Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd. (NASDAQ: CGEN), presented Compugen’s Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets. As part of her presentation covering the unique discovery capabilities of this platform, Dr. Cohen-Dayag presented experimental data demonstrating the potential of two in silico predicted proteins, CGEN-928 and CGEN-15001T, to serve as new targets for monoclonal antibody (“mAb”) based therapy.
Dr. Cohen-Dayag stated, "During the past two decades, mAbs have emerged as an important new and rapidly growing drug class, with over 20 mAbs already approved for therapeutic use in the U.S. for various clinical indications. mAb therapeutics have an exceptionally high success rate from first use in humans to regulatory approval, a rate more than double that of small molecule drugs. However, one of the main challenges in this extremely promising field is the identification of novel targets for mAb therapy. To this end, Compugen has developed several proprietary target discovery platforms through the focusing and integration of various aspects of its unique predictive discovery capabilities.”
Dr. Cohen-Dayag continued, “In addition to the two drug target candidates presented today in the conference, other promising candidates have entered our Pipeline Program and are at various stages of validation and mAb generation. We are now initiating collaborations with leading scientists from distinguished academic institutions in relevant scientific and medical fields to assist us in the further validation and development of these candidates."
In her presentation, Dr. Cohen-Dayag explained that CGEN-928 is a membrane protein which previously had no known function or potential clinical utility. However, Compugen’s Monoclonal Antibody Targets Discovery Platform predicted that this protein should have utility in the treatment of multiple myeloma, an important unmet medical need in oncology. Consistent with this prediction, CGEN-928 has now been shown by Compugen to be highly expressed in multiple myeloma samples compared with various normal tissue samples. Further studies have demonstrated broad expression of the protein in human multiple myeloma tumor cells, including late stage multiple myeloma and drug resistant and aggressive primary tumor cell lines. Thus CGEN-928’s expression profile and supporting data indicate its potential use as a target for antibody-based therapy, as well as a diagnostic and prognostic marker for multiple myeloma.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV